MSD starts pivotal trial of ROR1 drug in first-line lymphoma
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's position at the forefront of experimental therapies …